Endoscopy 2008; 40(5): 406-413
DOI: 10.1055/s-2007-995748
Original article

© Georg Thieme Verlag KG Stuttgart · New York

Transoral gastroplasty is safe, feasible, and induces significant weight loss in morbidly obese patients: results of the second human pilot study

C.  Moreno1 , J.  Closset1 , S.  Dugardeyn1 , M.  Baréa1 , A.  Mehdi1 , L.  Collignon1 , M.  Zalcman3 , M.  Baurain2 , O.  Le Moine1 , J.  Devière1
  • 1Department of Gastroenterology and Hepatopancreatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
  • 2Department of Anesthesiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
  • 3Department of Radiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
Further Information

Publication History

submitted 9 January 2008

accepted after revision 21 March 2008

Publication Date:
05 May 2008 (online)

Background and study aims: Bariatric surgical treatments have been proven to induce long-term weight loss in morbidly obese patients, but complications are relatively frequent. We recently reported a first human multicenter trial assessing the safety, feasibility, and weight loss results of the Transoral Gastroplasty (TOGA) system (Satiety Inc., Palo Alto, CA) at 6 months. Here we report the 6-month results of the second phase of the pilot trial with the TOGA system, with technical improvements to the device.

Patients and methods: Patients met established criteria for bariatric surgery. The TOGA system, a set of transoral endoscopically guided staplers, was used to create a stapled restrictive pouch along the lesser curvature of the stomach. Follow-up was at 1 week and at 1, 3, and 6 months. At 3 months, re-treatment consisting in additional distal restrictions was allowed if necessary.

Results: Data were available for 11 patients in our center (7 female, mean age 44.2 years, mean body mass index 41.6). The procedure was completed safely in all patients. There were no serious adverse events. Mean excess weight loss was 19.2 %, 33.7 %, and 46.0 % at 1, 3, and 6 months, respectively. Average body mass index decreased from 41.6 before treatment to 33.1 at 6 months. Absolute mean weight loss was 9.9 kg, 17.5 kg, and 24.0 kg at 1, 3, and 6 months, respectively. A dramatic improvement in quality-of-life measures was observed in all patients.

Conclusions: This second pilot trial confirmed the feasibility and safety of transoral gastroplasty. The early results and technical improvements reported in the present study are encouraging in terms of safety, early weight loss, and quality of life, and clearly allowed multicenter trials, which are planned to start soon.

References

  • 1 Haslam D W, James W PT. Obesity.  Lancet. 2005;  366 1197-1209
  • 2 DeMaria E J. Bariatric surgery for morbid obesity.  N Engl J Med. 2007;  356 2176-2183
  • 3 Li Z, Bowerman S, Heber D. Health ramifications of the obesity epidemic.  Surg Clin North Am. 2005;  85 681-701
  • 4 Wanless I R, Lentz J S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.  Hepatology. 1990;  12 1106-1110
  • 5 Abu-Abid S, Szold A, Klausner J. Obesity and cancer.  J Med. 2002;  33 73-86
  • 6 Engeland A, Bjorge T, Tverdal A. et al . Obesity in adolescence and adulthood and the risk of adult mortality.  Epidemiology. 2004;  15 79-85
  • 7 Wadden T A, Berkowitz R I, Womble L G. et al . Randomized trial of lifestyle modification and pharmacotherapy for obesity.  N Engl J Med. 2005;  353 2111-2120
  • 8 James W P, Astrup A, Finer N. et al . Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. Sibutramine Trial of Obesity Reduction and Maintenance.  Lancet. 2000;  356 2119-2125
  • 9 Pi-Sunyer F X, Aronne L J, Heshmati H M. et al, RIO-North America Study group . Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.  JAMA. 2006;  295 761-775
  • 10 NIH Technology Assessment Conference Panel . Methods for voluntary weight loss and control.  Ann Intern Med. 1993;  119 764-770
  • 11 Sjöström L, Lindroos A K, Peltonen M. et al . Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.  N Engl J Med. 2004;  351 2683-2693
  • 12 National Institutes of Health. . Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the Evidence Report.  Obes Res. 1998;  6 (Suppl 2) 51S-209S
  • 13 Roa P E, Kaidar-Person O, Pinto D. et al . Laparoscopic sleeve gastrectomy as treatment for morbid obesity: technique and short-term outcome.  Obes Surg. 2006;  16 1323-1326
  • 14 Himpens J, Dapri G, Cadiere G B. A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results after 1 and 3 years.  Obes Surg. 2006;  16 1450-1456
  • 15 Johnston D, Dachtler J, Sue-Ling H M. et al . The Magenstrasse and Mill operation for morbid obesity.  Obes Surg. 2003;  13 10-16
  • 16 Closset J, Mehdi A, Barea M. et al . Results of silastic ring vertical gastroplasty more than 6 years after surgery: analysis of a cohort of 214 patients.  Obes Surg. 2004;  14 1233-1236
  • 17 Colquitt J, Clegg A, Loveman E. et al . Surgery for morbid obesity.  Cochrane Database Syst Rev. 2005;  4 CD003641
  • 18 Awan A N, Swain C P. Endoscopic vertical band gastroplasty with an endoscopic sewing machine.  Gastrointest Endosc. 2002;  55 254-256
  • 19 Hu B, Chung S C, Sun L C. et al . Transoral obesity surgery: endoluminal gastroplasty with an endoscopic suture device.  Endoscopy. 2005;  37 411-414
  • 20 Kantsevoy S V, Hu B, Jagannath S B. et al . Technical feasibility of endoscopic gastric reduction: a pilot study in a porcine model.  Gastrointest Endosc. 2007;  65 510-513
  • 21 Deviere J, Ojeda Valdes G, Cuevas Herrera L. et al . Safety, feasibility and weight loss after transoral gastroplasty (TOGA): first human multicenter study.  Surg Endosc. 2008;  22 589-598
  • 22 http://www.sf-36.org/
  • 23 Kolotkin R L, Crosby R D, Kosloski K D, Williams G R. Development of a brief measure to assess quality of life in obesity.  Obes Res. 2001;  9 102-111
  • 24 Sjöström L, Narbro K, Sjöström C D. et al . Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects.  N Engl J Med. 2007;  357 741-752
  • 25 Nguyen N T, Wilson S E. Complications of antiobesity surgery.  Nat Clin Pract Gastroenterol Hepatol. 2007;  4 138-147
  • 26 Voitk A, Rizoli S, Joffe J. et al . Laparoscopic vertical banded gastroplasty: early results with the JOVO procedure.  Obes Surg. 2002;  12 62-64
  • 27 Egami K, Murohara T, Aoki M. et al . Ischemia-induced angiogenesis: role of inflammatory response mediated by P-selectin.  J Leukoc Biol. 2006;  79 971-976
  • 28 Nguyen N, Varela E J, Nguyen T. et al . Quality of life assessment in the morbidly obese.  Obes Surg. 2006;  16 531-533

C. Moreno, MD, PhD 

Division of Gastroenterology and Hepatopancreatology

Erasme University Hospital

808, route de Lennik

1070 Brussels

Belgium

Fax: +32-2-5554697

Email: christophe.moreno@erasme.ulb.ac.be

    >